Oropharynx Squamous Cell Carcinoma Clinical Trial
Official title:
Observational Parallel Cohort Study of Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell Carcinoma
The goal of this laboratory research study is to learn about symptoms and activity levels of patients with OPSCC that receive IMPT or TORS.
Baseline Visit:
If participant agrees to take part in this study, they will complete the following tests and
procedures at their baseline visit. This baseline visit will take place before participant's
treatment with IMPT or TORS:
- Participant will complete questionnaires about any symptoms of cancer they may be having
and how they affect their daily life at work and at home, their diet, and their speech.
- Participant will complete the Dysphagia Inventory. This is a questionnaire about how
difficult it is to swallow.
- The study staff will measure how wide participant can open their jaw to see if their
treatment may cause any jaw opening limitations.
It should take about 30 minutes to complete all of the questionnaires.
As part of participant's baseline visit, information below will be collected from their
medical record:
- Participant's medical history
- The results of participant's physical exam including their weight and any recent weight
loss.
- Any other diseases participant may have and any drugs they are currently taking.
- Participant's current smoking status and smoking history.
Activity Bands:
The study staff will either give participant an activity band at their baseline visit or they
will be mailed an activity wristband. Participant will be asked to wear the band 24 hours a
day for 1 week leading up to all study visits. The wristband will record how active
participant is and how much they sleep. The study staff will show participant how to wear and
use the wristband.
Study Visits:
Participant will complete the following study procedures after they complete treatment with
either IMPT or TORS, and at 3 and 6 months after that.
- The data from participant's wristband will be collected.
- Participant will complete the same questionnaires they did at baseline.
- At participant's 3 month visit only, the study staff will measure how wide they can open
their jaw to see if their treatment may cause any jaw opening limitations.
IMPT patients only:
If participant is receiving IMPT, they will complete the questionnaires they completed at the
baseline visit once a week while they are receiving treatment.
Length of Study:
Participant's active participation in this study will be over after the 6 month study visit.
Participant will return the wristband to the study staff after their participation is over.
If participant loses or damages the wristband while they are on study, another one will be
provided to them at no cost.
This is an investigational study.
Up to 44 participants will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03829722 -
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT04359199 -
QUantitative Assessment of Swallowing After Radiation (QUASAR)
|
||
Suspended |
NCT04916002 -
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
|
Phase 2 | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Active, not recruiting |
NCT03715946 -
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
|
Phase 2 | |
Recruiting |
NCT05451303 -
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
|
||
Recruiting |
NCT04858269 -
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
|
Phase 2 | |
Recruiting |
NCT05278039 -
Training Swallowing Initiation During Expiration
|
N/A | |
Recruiting |
NCT05649865 -
Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV)
|
||
Recruiting |
NCT06088381 -
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
|
Phase 2 | |
Recruiting |
NCT04124198 -
Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma
|
N/A | |
Withdrawn |
NCT04892875 -
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05904327 -
Circulating Biomarkers in Oropharyngeal Cancers
|
||
Active, not recruiting |
NCT03381183 -
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma
|
Phase 1 | |
Recruiting |
NCT04445064 -
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
|
Phase 2 | |
Recruiting |
NCT05582122 -
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
|
Phase 2 | |
Recruiting |
NCT04725396 -
Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC
|
N/A | |
Completed |
NCT03148665 -
Saliva-based Detection of CD44
|